194 related articles for article (PubMed ID: 33269259)
1. Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis.
Dajani AI; Popovic B
World J Clin Cases; 2020 Nov; 8(21):5235-5249. PubMed ID: 33269259
[TBL] [Abstract][Full Text] [Related]
2. Effects of aerobic exercise on metabolic indicators and physical performance in adult NAFLD patients: A systematic review and network meta-analysis.
Liu Y; Xie W; Li J; Ossowski Z
Medicine (Baltimore); 2023 Apr; 102(14):e33147. PubMed ID: 37026928
[TBL] [Abstract][Full Text] [Related]
3. Fatty acid and non-alcoholic fatty liver disease: Meta-analyses of case-control and randomized controlled trials.
Guo XF; Yang B; Tang J; Li D
Clin Nutr; 2018 Feb; 37(1):113-122. PubMed ID: 28161092
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of Huazhi Rougan granule in the treatment of non-alcoholic fatty liver: a systematic review and meta-analysis.
Wang T; Song J; Hu J; Feng S; Zhang H; Wang H; Li B
Ann Palliat Med; 2021 Dec; 10(12):12969-12984. PubMed ID: 33691456
[TBL] [Abstract][Full Text] [Related]
5. Effects of Synbiotics, Probiotics, and Prebiotics on Liver Enzymes of Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis.
Kanchanasurakit S; Kositamongkol C; Lanoi K; Nunta M; Saetuan T; Chaiyakunapruk N; Saokaew S; Phisalprapa P
Front Nutr; 2022; 9():880014. PubMed ID: 35669067
[TBL] [Abstract][Full Text] [Related]
6. Does the Mediterranean Diet Have Any Effect on Lipid Profile, Central Obesity and Liver Enzymes in Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects? A Systematic Review and Meta-Analysis of Randomized Control Trials.
Del Bo' C; Perna S; Allehdan S; Rafique A; Saad S; AlGhareeb F; Rondanelli M; Tayyem RF; Marino M; Martini D; Riso P
Nutrients; 2023 May; 15(10):. PubMed ID: 37242133
[TBL] [Abstract][Full Text] [Related]
7. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis.
Khan MY; Mihali AB; Rawala MS; Aslam A; Siddiqui WJ
Eur J Gastroenterol Hepatol; 2019 Jun; 31(6):703-715. PubMed ID: 31009401
[TBL] [Abstract][Full Text] [Related]
8. Acupoint embedding therapy improves nonalcoholic fatty liver disease with abnormal transaminase: A PRISMA-compliant systematic review and meta-analysis.
Dai L; Ooi VV; Zhou W; Ji G
Medicine (Baltimore); 2020 Jan; 99(3):e18775. PubMed ID: 32011470
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease.
Zhu K; Kakkar R; Chahal D; Yoshida EM; Hussaini T
World J Gastroenterol; 2023 Oct; 29(37):5327-5338. PubMed ID: 37899788
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of HuoXueHuaYu therapy for nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trial.
Cai Y; Liang Q; Chen W; Chen M; Chen R; Zhang Y; Xiao Y; Chen L
BMC Complement Altern Med; 2019 Jul; 19(1):178. PubMed ID: 31324247
[TBL] [Abstract][Full Text] [Related]
11. Association between nonalcoholic fatty liver disease and colorectal adenoma: a systematic review and meta-analysis.
Ding W; Fan J; Qin J
Int J Clin Exp Med; 2015; 8(1):322-33. PubMed ID: 25785003
[TBL] [Abstract][Full Text] [Related]
12. Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta-analysis of randomized controlled trials.
Goodarzi R; Sabzian K; Shishehbor F; Mansoori A
Phytother Res; 2019 Mar; 33(3):561-570. PubMed ID: 30653773
[TBL] [Abstract][Full Text] [Related]
13. Xiaoyao Powder in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Liu N; Yang J; Ma W; Li C; An L; Zhang X; Zou Q
J Ethnopharmacol; 2022 Apr; 288():114999. PubMed ID: 35051605
[TBL] [Abstract][Full Text] [Related]
14. Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.
Bandyopadhyay S; Samajdar SS; Das S
Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102174. PubMed ID: 37380128
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Dong Y; Lv Q; Li S; Wu Y; Li L; Li J; Zhang F; Sun X; Tong N
Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):284-295. PubMed ID: 28065744
[TBL] [Abstract][Full Text] [Related]
16. Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Loman BR; Hernández-Saavedra D; An R; Rector RS
Nutr Rev; 2018 Nov; 76(11):822-839. PubMed ID: 30113661
[TBL] [Abstract][Full Text] [Related]
17. Bezafibrate for primary biliary cirrhosis.
Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2012 Jan; 1():CD009145. PubMed ID: 22259000
[TBL] [Abstract][Full Text] [Related]
18. Effect of Exercise Training on Serum Transaminases in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Hong F; Liu Y; Lebaka VR; Mohammed A; Ye W; Chen B; Korivi M
Front Physiol; 2022; 13():894044. PubMed ID: 35837021
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
